NCT03773952View on ClinicalTrials.gov

Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

May 27, 2021

Study Completion Date

May 27, 2021

Conditions

Ulcerative Colitis

Interventions

DRUG

PBF-677

oral small molecule, antagonist of Adenosine A3 receptor (AA3R)

DRUG

Placebo oral capsule

Oral capsules

Trial Locations (1)

Unknown

Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid

All Listed Sponsors

collaborator

Qualitecfarma

UNKNOWN

lead

Palobiofarma SL

INDUSTRY

NCT03773952 - Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients | Biotech Hunter | Biotech Hunter